NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
Provided By GlobeNewswire
Last update: Dec 10, 2024
-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p<0.0001) --
Read more at globenewswire.comNASDAQ:NAMSW (6/17/2025, 12:50:26 PM)
8.82
-0.72 (-7.55%)
NASDAQ:NAMS (6/17/2025, 1:20:03 PM)
18.9284
-0.82 (-4.16%)
Find more stocks in the Stock Screener
